journal article·2012-06

Sustained delivery of SDF-1α from heparin-based hydrogels to attract circulating pro-angiogenic cells

Silvana Prokoph, Emmanouil Chavakis, Kandice R. Levental, Andrea Zieris, Uwe Freudenberg, Stefanie Dimmeler, Carsten Werner

Biomaterials· Volume 33· Issue 19
Publisher page

Abstract

Enrichment of progenitor cells in ischemic tissue has become a promising therapeutic strategy in the treatment of myocardial infarction. Towards this aim, we report a biology-inspired concept using sulfated glycosaminoglycans to sustainably generate chemokine gradients for the localized accumulation of early endothelial progenitor cells (eEPCs). StarPEG-heparin hydrogels, which have been previously demonstrated to support angiogenesis, were functionalized with SDF-1α, a potent chemoattractant known to act on EPCs. The gels were quantitatively shown to release the chemokine in amounts that are adjustable by the choice of loading concentrations and by matrix metalloprotease (MMP) mediated hydrogel cleavage. Transwell assays confirmed significantly enhanced migration of early EPCs towards concentration gradients of hydrogel-delivered SDF-1α in vitro. Subcutaneous implantation of SDF-1α-releasing gels in mice resulted in massive infiltration of early EPCs and subsequently improved vascularization. In conclusion, sustained delivery of SDF-1α from pro-angiogenic starPEG-heparin hydrogels can effectively attract early EPCs, offering a powerful means to trigger endogenous mechanisms of cardiac regeneration.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Angiogenesis and VEGF in Cancer · Proteoglycans and glycosaminoglycans research · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Heart disease and stroke statistics-2011 update: a report from the American heart association
2. Cell-based therapy of myocardial infarction10.1161/ATVBAHA.107.155317 ↗
3. Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy10.1016/j.addr.2010.03.001 ↗
4. Substrates for cardiovascular tissue engineering10.1016/j.addr.2011.01.007 ↗
5. Biomaterial strategies for alleviation of myocardial infarction10.1098/rsif.2011.0301 ↗
6. Custom design of the cardiac microenvironment with biomaterials10.1161/01.RES.0000173376.39447.01 ↗
7. Integration of multiple cell-matrix interactions into alginate scaffolds for promoting cardiac tissue regeneration10.1016/j.biomaterials.2010.11.008 ↗
8. Homing of progenitor cells to ischemic tissues10.1089/ars.2010.3582 ↗
9. Role of the SDF-1/CXCR4 system in myocardial infarction10.1253/circj.CJ-09-1021 ↗
10. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells10.1182/blood-2003-12-4423 ↗
11. Characterization of the stromal cell-derived factor-1α-heparin complex10.1074/jbc.M008110200 ↗
12. Endothelial progenitor cells: characterization and role in vascular biology10.1161/01.RES.0000137877.89448.78 ↗
13. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization10.1161/01.CIR.0000055313.77510.22 ↗
14. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis10.1186/1755-1536-1-4 ↗
15. Stem cells and the regeneration of the aging cardiovascular system10.1161/01.RES.0000261964.19115.e3 ↗
16. Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back10.1161/CIRCULATIONAHA.109.901405 ↗
17. Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure10.1038/gt.2011.18 ↗
18. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction10.1161/CIRCULATIONAHA.107.718718 ↗
19. Synergistic effects of the dual release of stromal cell-derived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration10.1016/j.biomaterials.2010.12.052 ↗
20. A stromal cell-derived factor-1 releasing matrix enhances the progenitor cell response and blood vessel growth in ischaemic skeletal muscle10.22203/eCM.v022a09 ↗
21. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing10.3727/096368909X481782 ↗
22. Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres10.1016/j.biomaterials.2011.03.027 ↗
23. Prolonged transendothelial migration of human haematopoietic stem and progenitor cells (HSPCs) towards hydrogel-released SDF110.1007/s00277-011-1155-x ↗
24. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response10.1016/j.biomaterials.2010.01.144 ↗
25. Migration of marrow stromal cells in response to sustained release of stromal-derived factor-1alpha from poly(lactide ethylene oxide fumarate) hydrogels10.1016/j.ijpharm.2009.12.063 ↗
26. Swelling equilibrium of a binary polymer gel10.1021/ma1019363 ↗
27. Freudenberg U, Sommer JU, Levental KR, Welzel PB, Zieris A, Chwalek K, et al. Using mean field theory to guide biofunctional materials design. Adv Funct Mater. doi:10.1002/adfm.201101868, in press.10.1002/adfm.201101868 ↗
28. FGF-2 and VEGF functionalization of starPEG–heparin hydrogels to modulate biomolecular and physical cues of angiogenesis10.1016/j.biomaterials.2010.07.021 ↗
29. Two-tier hydrogel degradation to boost endothelial cell morphogenesis10.1016/j.biomaterials.2011.08.078 ↗
30. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels10.1016/j.jconrel.2011.06.042 ↗
31. A starPEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases10.1016/j.biomaterials.2009.06.002 ↗
32. Enzymatically degradable heparin–polyethylene glycol gels with controlled mechanical properties10.1039/B921616B ↗
33. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest;108:391–7.10.1172/JCI13152 ↗
34. Aligned fibrillar collagen matrices obtained by shear flow deposition10.1016/j.biomaterials.2008.06.016 ↗
35. New strategies for chemokine inhibition and modulation: you take the high road and I'll take the low road10.1016/S0006-2952(97)00182-2 ↗
36. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine10.1074/jbc.274.34.23916 ↗
37. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-110.1093/emboj/16.23.6996 ↗
38. Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells10.1189/jlb.72.2.353 ↗
39. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: support for an endothelium-dependent mechanism10.1016/j.cardiores.2005.12.005 ↗
40. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma10.1182/blood-2006-07-035857 ↗
41. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases10.1161/CIRCULATIONAHA.104.503433 ↗
42. Differential processing of stromal-derived factor-1a and stromal-derived factor-1 b explains functional diversity10.1182/blood-2003-08-2857 ↗
43. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV10.1074/jbc.M405392200 ↗
44. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment10.1182/blood.V91.1.100 ↗
45. Endothelial progenitor cells: new hope for a broken heart10.1161/01.CIR.0000074242.66719.4A ↗
46. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia10.1161/01.CIR.103.5.634 ↗
47. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration10.1038/nm0603-702 ↗
48. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta110.1089/scd.2007.0214 ↗